News
New Study Sheds Light on the Hidden Genetics of Metastatic Neuroendocrine Cancer
By Anna Greene, PhD, NETRF Director of Research Unlocking the Molecular Mysteries of Neuroendocrine Neoplasms (NENs) A study published this month by NETRF-funded Collaborative Grant
Clinical Trials Aim to Advance the Future of Neuroendocrine Cancer Care
Neuroendocrine cancer research continues to evolve, with a growing number of clinical trials exploring bold, highly targeted strategies aimed at treating advanced and high-grade disease.
CAR T-Cell Therapy for Neuroendocrine Cancer, Now in Clinical Trial, Receives FDA FAST TRACK Designation
(Boston, MA): The Neuroendocrine Tumor Research Foundation (NETRF) is proud to join Chimeric Therapeutics in announcing that CAR T-cell therapy using CHM CDH17 has been
New ALT Biomarker Enhances Prognostic Accuracy in Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (PanNETs) can have a variety of behaviors. Some stay slow-growing for years, while others take a sudden, aggressive turn, even when they’re
Belzutifan Approved for Pheo Para
In a breakthrough for those with advanced pheochromocytoma and paraganglioma (Pheo/Para), the U.S. Food and Drug Administration (FDA) has approved WELIREG® (belzutifan) as a treatment
Driving Progress in NET Research: An Interview with Dr. Anna Greene
In a recent interview with CancerNetwork®, Dr. Anna Greene, Director of Research at the Neuroendocrine Tumor Research Foundation (NETRF), spotlighted the foundation’s leadership as the
CAR T-cell Clinical Trial Expands to Fourth Site
Patient enrollment has begun at a fourth site for the world’s first CAR T-cell therapy clinical trial for neuroendocrine cancer. Winship Cancer Center at Emory
Unlocking Personalized Treatment for Lung Neuroendocrine Tumors
Lung neuroendocrine tumors (lung NETs) make up 20-30% of all neuroendocrine cancers, yet their diversity and complexity have long puzzled researchers and clinicians. Now, thanks
New Clinical Trial to Evaluate Plixorafenib for BRAF V600E-mutated Neuroendocrine Carcinoma
A new global clinical trial is evaluating the investigational drug FORE8394 (plixorafenib) for treatment of neuroendocrine carcinomas with BRAF V600E-mutations. The phase 2 study aims
New Trial to Evaluate Combination of Fulvestrant and 177Lu-DOTATATE in Advanced Pancreatic Neuroendocrine Tumors
A new clinical trial at the University of Chicago Medicine is evaluating the combination of 177Lu-DOTATATE with fulvestrant in patients with advanced pancreatic neuroendocrine tumors